Multiple studies have reported an elevated risk of hypertension, congestive heart failure, acute coronary syndrome, and MI among patients treated with anti-VEGF monoclonal antibodies like bevacizumab.583–585 Hence, balancing maligant angiogenesis and ischemic risks in future VEGF/VEGFR pathway treatments is crucial. The gene discussed is VEGFA; the disease is congestive heart failure.